A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

Nielsen et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d7af6eb1cb92dd1bb8bb2b — DOI: https://doi.org/10.1158/1078-0432.ccr-10-1282

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Discovery and validation of breast cancer subtypes· 2006 · 129 citations
2. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)· 2005 · 2,073 citations
3. REporting recommendations for tumor MARKer prognostic studies (REMARK)· 2005 · 559 citations
4. Gene expression profiling predicts clinical outcome of breast cancer· 2002 · 9,592 citations
5. Cox Analysis of Survival Data with Non-Proportional Hazard Functions· 1992 · 190 citations